Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.31 |
| ▸ | OXTR | P30559 | 1/20 | 0.31 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL577643 | 1.00 | TSHR (0.36) | TSHRADRA2AADRA1DADRA1AADRA1B | |
| SCHEMBL6399596 | 0.88 | — | — | |
| SCHEMBL1450556 | 0.69 | TSHR (0.33) | TSHRDRD2DRD3 | |
| SCHEMBL577648 | 0.68 | CYP19A1 (0.33) | — | |
| SCHEMBL37725 | 0.68 | CYP19A1 (0.33) | — | |
| SCHEMBL4912110 | 0.67 | TSHR (0.43) | TSHRADRA2AADRA1AL3MBTL1DRD2 | |
| SCHEMBL2537276 | 0.67 | HRH1 (0.36) | TSHRADRA1ADRD2 | |
| SCHEMBL3884 | 0.66 | TSHR (0.48) | TSHRL3MBTL1 | |
| SCHEMBL29395766 | 0.66 | — | — | |
| SCHEMBL149347 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | claimed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | claimed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | claimed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | claimed |
| EP-1951046-A2 | METHODS TO ENHANCE CHEMOTHERAPY | Genzyme Corporation (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007022523-A2 | METHODS TO ENHANCE CHEMOTHERAPY | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | claimed |
| US-20070043012-A1 | Methods to enhance chemotherapy | GENZYME CORPORATION | 2007-02-22 | — | — | US | claimed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | claimed |
| WO-2024129931-A1 | ALPHA-V BETA-6(ανβ6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | GENZYME CORP (US) | 2022-12-29 | — | — | US | disclosed |
| CN-113490663-A | Pyridazine (thio) amides as fungicidal compounds | 拜耳公司 | 2021-10-08 | — | — | CN | disclosed |
| EP-3887362-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | Bayer Aktiengesellschaft (DE) | 2021-10-06 | — | — | EP | disclosed |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED, INC. (CA) | 2003-11-27 | — | — | US | disclosed |
| WO-2003055876-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | ANORMED INC. (CA) | 2003-07-10 | — | — | WO | disclosed |
| EP-1070052-A1 | FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP | AVENTIS CROPSCIENCE S.A. (FR) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999051579-A1 | FUNGICIDE COMPOSITIONS COMPRISING A HYDROXIMIC OR HYDRAZONIC GROUP | AVENTIS CROPSCIENCE S.A. (FR) | 1999-10-14 | — | — | WO | disclosed |
| EP-0314852-B1 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA GEIGY AG (CH) | 1993-11-18 | — | — | EP | disclosed |
| US-4921955-A | Process for the synthesis of 1-substituted imidazole-5-carboxylic acids and carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | TSHR 2155/4885ADRA2A 4778/4885ADRA1D 4511/4885 |
| US-20030220341-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CCR5, CXCR4, CXCR3 | TSHR 1370/4885ADRA2A 1950/4885ADRA1D 1765/4885 |
| US-20070043012-A1 | Methods to enhance chemotherapy | CXCR4, MCL1, CXCL12 | TSHR 1330/4885ADRA2A 647/4885ADRA1D 1697/4885 |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | TSHR 3019/4885ADRA2A 890/4885ADRA1D 385/4885 |
| US-20220409589-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY | CCR5, CXCR4, CXCR3 | TSHR 1370/4885ADRA2A 1950/4885ADRA1D 1765/4885 |
| US-20230054449-A1 | PYRIDAZINE (THIO)AMIDES AS FUNGICIDAL COMPOUNDS | PNPO, TPMT, BLVRB | TSHR 1426/4885ADRA2A 3354/4885ADRA1D 4505/4885 |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | TSHR 4313/4885ADRA2A 3890/4885ADRA1D 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.